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Background: In a previous analysis on the patients with ovarian cancers, we have found that clusterin is a
biomarker associated with ovarian cancer in vivo and may be a prognostic factor associated with adverse outcome.
Here, we explored the effect of lentivirus-mediated shRNA interference of clusterin, investigated whether clusterin
was associated with adverse outcome of ovarian cancer cells in vitro.
Methods: OVCAR-3 and TOV-21G cell lines were infected with the lentivirus for delivering clusterin shRNA, and the
stably transfected cells were selected. The effect of clusterin silencing was detected by western blotting assay. The
proliferation, clonability, migration, invasion and cell cycle of two cell lines were detected separately by MTT assay,
clone formation assay, scratch assay, transwell assay and fluorescence-activated cell sorting.
Results: Following clusterin silencing with shRNA, the expression of clusterin in two cell lines were decreased. And
the proliferation, clonability, migration, invasion of these two cell lines were down-regulated apparently. The cell
cycle of two cell lines was disturbed, cells in G1 phase was increased, but cells in G2 and S phase was decreased.
Conclusions: The expression of clusterin is significantly correlated with the biological characteristics of ovarian
cancer cells, it may be a potential molecular for ovarian cancer treatment.
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Ovarian cancer, a major cause of death in all gynecologic
malignancies, is one of the most common malignancy in
women worldwide and is the fourth leading cause of
death from malignant disease [1]. Recently, the incidence
of ovarian cancer has been increasing in China,
Singapore and other countries [2]. With optimal surgical
treatment and standard chemotherapy, the 5-year sur-
vival rate of ovarian cancer patients has improved sig-
nificantly [3]. Nevertheless, the preliminary success in
tumor regression and recurrence can’t prevent resistance
to further chemotherapeutic treatment. Development of
this further resistance suggests the major limitation to
the treatment. Hence, there is a crying need to look for
a suitable solution for further treatment.* Correspondence: pgf_yang@126.com
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widely used in tumor treatment. Lots of reports show
that there are many specific genes which related to
tumor genesis and development of the ovarian cancer,
such as CIP2A [4], HOX [5], BRIP1 [6], EIF5A2 [7] and
Bmi-1 [8]. Our previous studies suggested clusterin was
probably another gene relevant to the treatment of ovar-
ian cancer.
Clustein is a highly conserved, heterodimeric-secreted
glycoprotein, which is encoded by a single copy gene lo-
cated on chromosome 8p21-p12. Clustein is known as
apolipoprotein J, estosterone-repressed prostate message-
2, or sulfated glycoprotein-2. Clusterin gene expression is
complex, appearing as different forms in different cell
compartments [9]. Recent studies indicated that clusterin
gene expressed in kinds of human tumor cells, including
liver cancer cells, prostate cancer cells, colon cancer cells
and bladder cancer cells [10–13]. The clusterin expressionistributed under the terms of the Creative Commons Attribution 4.0 International
by/4.0/), which permits unrestricted use, distribution, and reproduction in any
t to the original author(s) and the source, provide a link to the Creative
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pression was closely related to the tumorigenesis of the
tumor.
Previous research reveal clusterin was up-regulated in
the ovarian cancer cells and the overexpression of clus-
terin did affect the tumorigenesis of the tumor [14]. To
further study the function of clusterin, we silented the
clusterin gene of ovarian cancer cells with the lentivirus
vector in vitro and detected the clusterin gene expression
in silenced-tumor cells. Moreover, we assessed the prolif-
eration, migration, invasion, clonability, cell cycle of ovar-
ian carcinoma cells after clusterin gene silencing.Materials and methods
Cell line and culture conditions
Human ovarian cancer cell lines OVCAR-3 and TOV-
21G were obtained from Sun Yat-Sen University Cancer
Center (Guangzhou, China). Human ovarian cancer cell
lines HO8910 and HO8910PM were purchased from
Shanghai cell bank of Chinese academy of sciences.
OVCAR-3, HO8910 and HO8910PM cells were growth
in RPMI1640 mediumwith 10 % (v/v) fetal calf serum,
streptomycin (100 U/ml) and penicillin (100 U/ml). TOV-
21G were growth in MCDB105, Medium199 mixed
Medium (1:1) with 10 % (v/v) fetal calf serum, strepto-
mycin (100 U/ml) and penicillin (100 U/ml). RPMI1640
medium, fetal bovine serum (FBS) and Dimethylsulfoxide
(DMSO) were purchased from Gibco Biotechnology
(Gibco-BRL, MD, USA). MCDB105, Medium199 were
purchased from Sigma (USA). Cultures were maintained
at 37 °C in an incubator with a humidified atmosphere of
5 % CO2.Western blotting to analyze the clusterin gene expression
in tumor cells
For western blotting analysis, cells were seeded in 6-well
plates at 2×105/well. Cells were grown to 90 % confluence
and were lysed in cell Lysis solution (RIPA: PMSF = 100:1)
for 30 min and were transferred to 1.5 ml EP for 30 min
on ice. Lysates were centrifuged at 12000 g for 30 min to
remove nuclei and precipitates. Supernatant protein con-
centrations were measured using the Bio-Rad protein
assay (OD:562 nm) with BSA in lysis buffer as a standard.
Cell lysates were loaded into each well containing SDS-
PAGE and transferred to nitrocellulose membranes. The
protein concentration were adjusted to 40 μl. Membranes
were blocked for 2 h at room temperature in 0.1 % TBS
with 5 % non-fat milk, and probed using Clusterin anti-
body (1:100) purchased from Millipore (Billerica, MA,
USA) andα-tubulin (1:1000) as the internal control pur-
chased from (Santa Cruz, CA, USA) overnight. After the
membrane washing three times by 0.1 % TBS, the second-
ary antibody was added and incubated 2 h at roomtemperature. Then the bands were visualized by an ECL
kit (ThermoScientific Pierce).Lentivirus constructions
ShRNA was designed by Shanghai Jikai gene Chemical
Co., Ltd. (Shanghai, China) and referred to Clusterin
Gene (NM_203339) of GeneBank. The PGCSIL-GFP,
which is a third generation self-inactivating lentivirus
vector containing a CMV-driven GFP reporter and a U6
promoter upstream of cloning restriction sites, was
used in the shRNA silencing system. The synthetic





mers were annealed and linked into the cloning restric-
tion site of the vector which had been digested with the
restriction enzymes AgeI and EcoRI. After annealing, the
double-stranded DNA was digested with EcoRI to
linearize the pGCSIL-GFP vector. The negative control
sequence (5’-ttctccgaac gtgtcacgt-3’) was used as previ-
ously described. The NC-shRNA was designed; forward
forward (5’-ccggaaccagagctcgcccttctacttcaagagagtagaaggg
cgagctctggtttttttg-3’) and reverse (5’-aattcaaaaaaaccagag
ctcgcccttctactctcttgaagtagaagggcgagctctggtt-3’). It has
been proven to be efficient in Clusterin silencing exper-
iments. Then it was co-transfected with pHelper 1.0
and pHelper 2.0 into 293T cells to package and produce
the shRNA expressing lentivirus. The supernatant was
collected and concentrated 48 h after co-transfection.
The titer of lentivirus targeting Clusterin (LV-CLU) and
lentivirus targeting negative control (LV-NC) was ex-
amined by the hole by dilution titer method. The vec-
tors and oligonuleotide primers were purchased from
Genechem. To knock down the Clusterin in the
OVCAR-3 and TOV-21G cancer cell lines, cells were
seeded in a 6-well tissue culture plate with 2×105/well
1 day prior to infection. The complete culturesolution
was replaced by infection enhancing solution with 5
μg/ml polybrene (Genechem) and the packed lentivirus
was added to cells with multiplicity of infection (MOI)
20 or 10. Twelve hours later, the lentivirus solution was
replaced with complete culture solution. Infected cells
were subcultured every 5–7 days [13].Test the infection and knockdown efficiency
The human tumor cells grew well on the day prior to
viral introduction was recovered, and were incubated
with 5 % CO2 at 37 °C. Following the incubation, the ex-
pression of GFP was observed under a fluorescence
microscope. When the efficiency of infection exceeded
50 %, Cells were collected. The protein expression of
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above.
MTT assay and clone formation assay to detect the
proliferation of ovarian cancer cells
Cells were cultured in the 6-well plates at 2×105/well.
When cells were grown to 80 % confluence, they were
trypsinized. The cell suspension was re-suspended in
complete medium. Cells were counted and added in
96-well plate at 1000 cells/well. Each group, included
three compound perforations, added 100μl complete
medium. Cells were incubated with 5 % CO2, 37 °C. The
growth of cells were tested with Enzyme immunoassay
for four days. The data were collected and analyzed to
create a proliferation curve.
Meanwhile, the suspending cells were transferred into
six-well plate at 300 cells/well. Each well was added 2 ml
complete medium and comprised three compound per-
forations. Cells were incubated with 5 % CO2 and cul-
tured at 37 °C until the cell clones could be observed
directly. The medium was removed, methanol was added
for 30 min. Removing methanol, the clones were dyed
with crystal violet for 30 min and counted.
Scratch assay and transwell assay to detect the migration
and invasion of ovarian cancer cells
Cells were cultured six-well plate at 5 × 105 cells/well.
Each well was added 2 ml complete medium with 10 %Fig. 1 Establishment of stable CLU silencing OVCAR-3 and TOV-21G cell lin
The results of gene sequencing showed that OVCAR-3 and TOV-21G cells w
(b) Analysis of levels of Clusterin protein in OVCAR-3 and TOV-21G cells. Re
level of Clusterin expression. c Clusterin (GFP) expression in OVCAR-3 and T
infection efficiency of OVCAR-3 cells (MOI 20) and TOV-21G cells (MOI 10) w
later, the infection efficiency achieved was >90 %PFA and comprised three compound perforations.
Cells were incubated with 5 % CO2 and cultured at
37 °C. When cells were covered almost confluent, the
surface of cells was scratched by the same pin and
washed twice with PBS, allowed to migrate in RPMI1640
without FBS for 24 h. Phase contrast micrograph images
were captured immediately and 24 h later. The relative
distance traveled by the leading edge from 0 to 22 h was
assessed using Adobe Photoshop CS3 software (Adobe
Inc.) (n = 6).
Cells were transferred into 24-well plate at 5 × 104
cells/well and cultured as above for 24 h. After trypsi-
nized, cells washed with PBS and resuspended in
RPMI-1640 without FBS. Samples of 5 × 104 cells
were placed in the upper chamber of each Transwell
device (Falcon, BD Labware, Bedford, MA, USA) with
an 8-μm Matrigel-coated polycarbonate membrane
filter inserted in 24-well plates. RPMI-1640 with 10 %
FBS was placed in the lower chamber. After 24 h of
incubation, the non-invading cells were removed by
wiping the upper surface of the filter with a cotton
swab. The remaining cells were fixed in 100 % metha-
nol for 20 min, stained with Giemsa (Sigma), and
rinsed with distilled water several times. The degree
of invasion was quantified by selecting five different
predetermined views (original magnification, x200)
and counting the cells on the underside of the filters
under a microscope [13].es. a Detection of lentivirus transfection in OVCAR-3 and TOV-21G cells.
ere transfected successfully LV-CLU or LV-NC gene with lentivirus
sults suggested that both OVCAR-3 and TOV-21G cells had the higher
OV-21G cells as detected by fluorescence microscope (x100). The
ere shown. The cells were infected with LV-CLU or LV-NC. Four days
Fig. 2 Clusterin protein expression in OVCAR-3 and TOV-21G cells
following knockdown of the clusterin gene. a the protein expression of
clusterin in the OVCAR-3 cells. The western blot analysis demonstrated
Clusterin protein expression reduced in LV-CLU group, while Clusterin
protein expression was almost unaffected by the LV-NC. b the protein
expression of clusterin in the TOV-21G cells. The results was the same
as the OVCAR-3 cells
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ovarian cancer cell cycle distribution following clusterin
gene silencing
Cells were cultured six-well plate at 5 × 105 cells/well. The
cell supernatant was collected when the coverage rate in
the experimental group increased to 80 %, ensuring that
cells were in the logarithmic phase. Cells were washed
twice with PBS and subjected to trypsinization. Cells were
collected in a 5 ml centrifuge tube. Three compound per-
forations were prepared in each group and timed cycle
tests were performed ensuring an adequate number of
cells for computerized analysis, with at least 1,000,000
each time. Cells were collected after centrifugation at
2,000 rpm for 5 min and fixed with 70 % ethanol, which
was pre-cooled to 4 °C overnight. The stationary liquid
was abandoned by centrifugation at 2000 rpm for 5 min.
Cells were washed with PBS twice. Cells were incubated
in PBS containing 400 μl RNase (50 μg/ml) at 37 °C for 30
min. Cells were then stained with 800 μl PI (20 μg/ml) for
30 min in the dark at 37 °C. Cell cycle progression was an-
alyzed using a flow cytometer (Beckman Coulter, Miami,
FL, USA). During cell cycle analysis, gating and voltage
were carefully set to exclude clumped cells and cell debris.
The data were analyzed using CXP Analysis 2.0 (Beckman
Coulter).
Statistical analysis
All data are analyzed with the statistical software SPSS
16.0 and expressed as mean ± standard deviation (SD).
The significance level of statistics was set at P < 0.05.
Results
The expression of clusterin protein in tumor cells
To select the cell lines with a high level of CLU exp-
ression, we used western blot analysis to analyze the
Clusterin expression at the protein levels in HO8910,
HO8910PM, OVCAR-3 and TOV-21G cancer cell lines.
The results of the western blotting, which set α-tublin as
an internal reference, suggested that the clusterin protein
was separately expressed in the HO8910, HO8910PM,
OVCAR-3 and TOV-21G cells (Fig. 1b). The levels of
clusterin protein were higher in the OVCAR-3 and TOV-
21G cells than in the HO8910 and HO8910PM cells. It
was found that the protein expression level of two cell
lines was different, but was abundant.
Transfected with the shRNA lentivirus, GFP expression
was observed under fluorescence microscopy (Fig. 1c).
The infection efficiency of OVCAR-3 cells (MOI 20) and
TOV-21G cells (MOI 10) were shown. The cells were in-
fected with LV-CLU or LV-NC. Four days later, the infec-
tion efficiency achieved was >90 %. The level of GFP
expression reached respectively the highest levels on the
fourth day. To further, the gene sequence of the OVCAR-
3 and TOV-21G cells were sequenced (Fig. 1a). The levelsof CLU protein in the OVCAR-3 and TOV-21G cells were
detected by western blotting. The results showed that the
levels of CLU protein were significantly lowered in cells of
LV-CLU groups. However, there was no significantly influ-
ence in the NC-CLU groups (Fig. 2).
Analysis of inhibition of the proliferation of ovarian cancer
cells following down-regulation of the clusterin gene
The proliferation of ovarian cancer cells were detected by
MTT assay. After transfection with the shRNA lentivirus,
the proliferation rate of OVCAR-3 cells in LV-CLU group
was inhibited together with the NC-CLU control from
the third day (Fig. 3). And compared with the NC-CLU
control, the proliferation rate of TOV-21G cells in the
LV-CLU group was inhibited from the second day
(Fig. 3). The results show that down-regulation of the
clusterin gene in two cell lines were obvious.
Analysis of inhibition of the migration following clusterin
gene silencing
The migration of tumor cells were detected by scratch
assay and observed under microscopes. The two groups
were treated with a pin, respectively, for 24 h. The cells
Fig. 3 The results of the migration following Clusterin gene silencing (a) A scratch assay was used to detect the migration ability of TOV-21G
cells after Clusterin silencing. The two groups were treated with a pin, respectively, for 24h. The cells of LV-CLU group had a greater migrating
distance compared to the cells of NC-CLU group. (b) A scratch assay was used to detect the migration ability of OVCAR-3 cells after Clusterin
silencing. The results was similar to the TOV-21G cells
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pared to the cells of NC-CLU group after 24 h. The re-
sults was similar to the TOV-21G cells (Fig. 3). This
results suggest that the migration of OVCAR-3 and
TOV-21G cells after the transfection was diminished.
Analysis of inhibition of the invasion following clusterin
gene silencing
Invasion is an important aspect that lead to the ability of
cancer cells to metastasize. In our study, transwell assay
was used to detect whether Clusterin silensing would affect
cell invasion. Cells of LV-NC and LV-CLU groups were
seeded in transwell chambers and cultured for 24 h. The re-
sults demonstrated that cells of LV-CLU group had less in-
vasiveness than cells of LV-CLU group. Statistical analysis
revealed a significant difference between the LV-NC and
LV-CLU groups (P < 0.01) (Fig. 4).
Analysis of inhibition of the clonability following clusterin
gene silencing
We observed a decrease in the number of OVCAR-3 and
TOV-21G cell colonies in the LV-CLU group afterFig. 4 The results of the invasion following clusterin gene silencing. Statis
LV-CLU groups. The results demonstrated that the cells of LV-CLU groups hclusterin gene silencing. The number of cells in the col-
onies decreased relative to the NC-CLU control (P < 0.05)
(n = 3) (Fig. 5). The results indicates that the clonability of
OVCAR-3 and TOV-21G cells largely inhibited following
the down-regulation of clusterin gene.
FACS analysis of cell cycle following clusterin gene
silencing
After transfection with the shRNA lentivirus, the per-
centage of OVCAR-3 and TOV-21G cell cells in the
G1 phase was significantly increased (P < 0.05), while
cells in the S (P < 0.001) and G2 phases decreased sig-
nificantly (P < 0.05) in the LV-CLU group compared
with the NC-CLU control (Fig. 6). The results indicates
that silence of the clusterin gene was apparently re-
lated to regular distribution of the OVCAR-3 and
TOV-21G cells.
Discussion
In recently reports, the expression level of clusterin was
studied in normal ovaries, benign and borderline ovarian
tumors, and malignant epithelial cancers. A significanttical analysis revealed a significant difference between the LV-NC and
ad less invasiveness
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served from the normal ovary, to benign cystadenoma,
borderline tumor, and malignant epithelial carcinoma.
These evidences suggest up-regulation of clusterin is as-
sociated closely with tumor progression [15]. The level
of clusterin expression maybe is an important prognostic
factor in the assessment of the aggressive nature of ovar-
ian cancer [2].
Clusterin is an controversial molecule and it remains
debatable about whether clusterin has multiple functions
or only a single primary function influenced by cellular
context [16]. It is not clear why clusterin play contradict-
ory functions, such as cell survival, tumor progression,
treatment resistance or cell apoptosis [17]. However, its
functions in many cancer cells are certain. The level of
clusterin expression in renal cancer cells was found to
be closely associated with pathological stage and grade
of the tumor, and the overall survival rate of patients
with high clusterin expression was obviously lower than
that of patients with weak expression [18]. The level of
clusterin expression correlated with the level of estrogen
and progesterone receptor expression, tumor size, and
lymph node metastasis in breast carcinoma [19]. In
colon carcinoma, clusterin has been used as a novel
prognostic and predictive marker which is observed in
aggressive tumors and metastatic nodules [20]. Similarly,
clusterin expression is associated with FIGO stage and
histological type in ovarian cancer [21]. Hence, throughFig. 5 A plate clone formation assay is shown. The data demonstrated tha
formation rate than the NC-CLU groups (P<0.05) (n=3)mechanisms not yet elucidated, it is certain that CLU
biosynthesis is altered and up-regulated in cancer
tissues.
In the preset study, we have showed that clusterin
express highly in two ovarian cancer cell lines in vitro,
while there is lower clusterin expression in the normal
ovarian cells [14]. And the clusterin expression could be
down-regulated with a lentiviral vector. Following the
clusterin silencing, the clusterin expression was down-
regulated, and the proliferation, clonability of OVCAR-3
and TOV-21G cells were decreased, meanwhile, the mi-
gration and invasion of these cells also down-regulated.
The cell cycle of these cells were changed. A large num-
ber of OVCAR-3 and TOV-21G cells were confined in
G1 phase, only a small number of these cells accessed
into G2 phase and S phase. In contrast, no-silencing
cells had a strong clusterin expression. They had signifi-
cantly higher abilities of proliferation, clonability, migra-
tion and invasion. Our data suggest that clusterin is an
important protein associated with both cancer therapy
and tumor development.
Our results also support that clusterin is a stress-
associated anti-apoptotic protein that is up-regulated in
an adaptive cell survival manner following various cell
death trigger in ovarian cancer cells [22, 23]. More evi-
dence suggests that clusterin enhance the resistance to
cytotoxic chemotherapy and radiotherapy in breast cancer
[24], lung cancer, cervical cancer, and prostate cancer.t OVCAR-3 and TOV-21G cells of LV-CLU group had a lower clone
Fig. 6 Changes in the cell cycle distribution of OVCAR-3 and TOV-21G cells in the knockdown group. After transfection with the shRNA lentivirus,
the percentage of OVCAR-3 and TOV-21G cell cells in the G1 phase was significantly increased (P<0.05), while cells in the S (P<0.001) and G2
phases decreased significantly (P<0.05) in the LV-CLU group compared with the negative control
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moresistance maybe is an novel therapeutic strategy.
Conclusions
In summary, present study demonstrated that the bio-
genesis of ovarian cancer cells was changed following
the silence of clusterin. And the proliferation, clonability,migration, invasion and cell cycle of ovarian cancer cells
are significantly correlated with the expression of clus-
terin. Therefore, clusterin could be a potential molecular
for ovarian cancer treatment. Our study may be helpful
to the development of new therapeutic regimens and im-
provement the subsequent survival in ovarian cancer
patients.
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